

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ANGELALIGN TECHNOLOGY INC.

時代天使科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6699)

POSITIVE PROFIT ALERT

This announcement is made by Angelalign Technology Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment of the Group’s unaudited management accounts for the year ended 31 December 2025 (“**FY 2025**”) and information currently available to the Company, the Group is expected to record a net profit for FY 2025 in the range of approximately USD24 million to USD30 million, representing an increase of 140% to 200% as compared to approximately USD10 million for the year ended 31 December 2024 (“**FY 2024**”).

The Board considers that the expected increase in the net profit was primarily attributable to the following factors:

1. **Increased adoption of the Group’s clear aligner solutions**, driven by strong clinical outcomes and customer service capabilities internationally, and by continued penetration into lower-tier markets and early treatment segment in China;
2. **Realization of operating leverage from the Group’s established global sales network, world-class global service and clinical support infrastructure**, as prior investments in localized sales, services and operational capabilities across key markets and centralized functions translated into improved efficiency and scale benefits;
3. **Delay in the ramp-up costs of certain non-China Manufacturing facilities**, which led to lower-than-expected capital expenditure and operating expenses for FY 2025;
4. **Timing of certain legal and professional expenses**, as certain intellectual property-related matters remained at preliminary procedural stages during FY 2025, resulting in a relatively limited financial impact within the reporting period; and
5. **A lower profit base in FY 2024 which was impacted by significant strategic investments.**

As at the date of this announcement, the Company is in the process of finalizing the annual results of the Group for FY 2025. The information contained in this announcement is only based on a preliminary assessment by the management of the Company with reference to the information currently available including the unaudited management accounts of the Group which have not been audited or reviewed by the Company's auditors or the audit committee of the Company, and the actual results of the Group for FY 2025 may be different from what is disclosed in this announcement, and are subject to further amendments and adjustments as required. Shareholders and potential investors are advised to read carefully the Group's annual results announcement for FY 2025, which is expected to be published before the end of March 2026 pursuant to the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, March 3, 2026

As at the date of this announcement, the Board comprises Mr. HU Jiezhong, Mr. HUANG Kun, Mr. SONG Xin and Ms. DONG Li as executive Directors; Mr. FENG Dai as a non-executive Director; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.